Mechanisms by which microbial cells might develop resistance

Slides:



Advertisements
Similar presentations
Mr. Safford’s Biological Sciences.  All enzymes are globular proteins thus spherical in shape  Control biochemical reactions in cells  They have the.
Advertisements

Antibiotics and Resistance Prepared by Stephanie Aldret Cell Physiology Fall 2002.
Inhibiting Microbial Growth in vivo CLS 212: Medical Microbiology.
Antibiotics.
Group Red – Demacia Gabe, Chris, Tom. - Enzymes with more than one polypeptide chain can change between an active shape and an inactive shape - When the.
1. Learning Targets What are antibiotics? Where do they come from? How does our antibiotic, streptomycin, kill bacteria? 2.
Treatment of Infectious Diseases. ›Drugs used to treat bacterial diseases are grouped into categories based on their modes of action Treatment of Bacterial.
Antimicrobial Drugs Chapter 20. I. Chemotherapeutics u A. History –Paul Ehrlich –Structural analogues »1935: Domagk.
Enzyme Regulation Chapter Biochemical Pathways Regulations of Enzymes Objective: I can identify and describe the different ways enzymes are regulated,
PRINCIPLES OF ANTIBIOTIC THERAPY
Chapter 2:Enzymes Higher Human Unit 1: Cell Function and Inheritance 7/7/20161Mrs Smith.
Drugs and Microbes.
From: The battle for chitin recognition in plant-microbe interactions
Antibiotic Resistance
Control of Metabolic Pathways (2)
ANTIMICROBIAL THERAPY
Regulation of the Cell Cycle & Cancer
Figure 3 The cell cycle and the role of CDK4/6 inhibition
Figure 4 Possible combination therapies CDK4/6 inhibitors
8.1 Metabolism Essential idea: Metabolic reactions are regulated in response to the cell’s needs.
Chemotherapeutic agent
Nat. Rev. Clin. Oncol. doi: /nrclinonc
A. Fajardo, J.F. Linares, J.L. Martínez 
Selected mechanisms of colistin resistance
Mutational resistance to fluoroquinolones and carbapenems involving chromosomally encoded mechanisms expressed by P. aeruginosa. Mutational resistance.
Pathogenic schemes of diarrheagenic E. coli.
Cartoon depiction of the salient features of a theoretical composite of Bacteroides fragilis and Bacteroides thetaiotaomicron that underscores the extent.
Electron micrographs of the binding of human vitronectin to complement-resistant (left) and complement-sensitive (right) strains of M. catarrhalis. Electron.
Scheme of dynamic SCV development in the course from acute to chronic infection. Scheme of dynamic SCV development in the course from acute to chronic.
Approximate numbers of cases per 100,000 individuals caused by penicillin resistance for each year (left). Approximate numbers of cases per 100,000 individuals.
MexT-associated downregulation of oprD expression.
Coregulation of mexEF-oprN and oprD in P. aeruginosa.
Pathways involved in regulation of macrophage iNOS synthesis and NO production in response to H. pylori. Pathways involved in regulation of macrophage.
Compare and contrast potential and kinetic energy
Increasing prevalence of multidrug resistance among P
Diagram of the group A streptococcal cell covered with an outer hyaluronic acid capsule and the group A carbohydrate, consisting of a polymer of rhamnose.
Results of in vivo competition experiments in a mouse model of systemic infection (median CI values are shown by horizontal lines). Results of in vivo.
Relationships between H. pylori, inflammation, and acid secretion.
Number of outbreaks associated with drinking water by water system type and year (n = 780), 1971 to “Other” includes outbreaks associated with bottled.
Percentages of outbreak deficiencies (n = 671) in public water systems (n = 656) by time period, 1971 to 2006, excluding outbreaks associated with Legionella.
Mechanism of macrophage apoptosis caused by H. pylori.
Selected host cell processes targeted by Dot/Icm effectors demonstrating the complexity of LCV biogenesis and maintenance as well as the broad range of.
Location of drug efflux pumps and pathways of drug influx and efflux across the OM and IM in Gram-negative bacteria. Location of drug efflux pumps and.
Drug transport mechanism of AcrB.
Β-Lactam hydrolysis of cephalosporin followed by nonenzymatic release of a leaving group (LG). β-Lactam hydrolysis of cephalosporin followed by nonenzymatic.
Transduction mechanisms
Fabrizio Dutly, and Martin Altwegg Clin. Microbiol. Rev. 2001; doi:10
Two different pharmacophoric domains attached covalently by a linker domain. Two different pharmacophoric domains attached covalently by a linker domain.
Dysregulation of the apical-junctional complex by H. pylori.
Staphylococcus aureus and Staphylococcus epidermidis cell surface proteins, known as microbial surface components recognizing adhesive matrix molecules.
Examples of tobramycin-efflux pump hybrids: tobramycin linked to 1-(1-naphthylmethyl)-piperazine (NMP) (hybrid 14), tobramycin linked to paroxetine (hybrid.
(A) Mucus breakdown. (A) Mucus breakdown. S. pneumoniae colonization of the nasopharynx is facilitated by mucus degradation by the enzymes NanA, BgaA,
Pharmacodynamics BSCI 493 March 2008.
Replication and intercellular transmission of HIV-1 is increased during antigen presentation. Replication and intercellular transmission of HIV-1 is increased.
Model of the assembled tripartite drug efflux pump.
Schematic description of sites of action of different antifungal agents. Schematic description of sites of action of different antifungal agents. Candins.
Intermediary pathways to synthesis of pyruvate
Proposed mechanisms of Ag presentation.
Enzymatic pathway for the synthesis ofN-acetylgalactosamine, the major carbohydrate portion of the cyst wall. Enzymatic pathway for the synthesis ofN-acetylgalactosamine,
Bacterial architecture and targets for biosensing.
Structure and function of RND efflux pumps in P. aeruginosa.
Pathogenesis of oncogenic HPV
Relationship between MIC, dose of fluconazole, and emergence/expression of specific resistance mechanisms in oropharyngeal candidiasis. •, MIC of fluconazole.
Cytokines and cytokine receptors involved in type I immunity in tuberculosis. Cytokines and cytokine receptors involved in type I immunity in tuberculosis.
Mechanism of molecular transport from serum into salivary gland ducts.
PTEN and p53: Who will get the upper hand?
Schematic representation of the interaction between amphotericin B and cholesterol in a phospholipid bilayer. Schematic representation of the interaction.
Functions of selected IFN-inducible proteins.
Figure 1 Infection and resistance in urological practice
Presentation transcript:

Mechanisms by which microbial cells might develop resistance Mechanisms by which microbial cells might develop resistance. 1, The target enzyme is overproduced, so that the drug does not inhibit the biochemical reaction completely. 2, The drug target is altered so that the drug cannot bind to the target. 3, The drug is pumped out by an efflux pump. 4, The entry of the drug is prevented at the cell membrane/cell wall level. 5, The cell has a bypass pathway that compensates for the loss-of-function inhibition due to the drug activity. 6, Some fungal “enzymes” that convert an inactive drug to its active form are inhibited. 7, The cell secretes some enzymes to the extracellular medium, which degrade the drug. Mechanisms by which microbial cells might develop resistance. 1, The target enzyme is overproduced, so that the drug does not inhibit the biochemical reaction completely. 2, The drug target is altered so that the drug cannot bind to the target. 3, The drug is pumped out by an efflux pump. 4, The entry of the drug is prevented at the cell membrane/cell wall level. 5, The cell has a bypass pathway that compensates for the loss-of-function inhibition due to the drug activity. 6, Some fungal “enzymes” that convert an inactive drug to its active form are inhibited. 7, The cell secretes some enzymes to the extracellular medium, which degrade the drug. Mahmoud A. Ghannoum, and Louis B. Rice Clin. Microbiol. Rev. 1999; doi:10.1128/CMR.12.4.501